Literature DB >> 15518814

Identification of the 5' sequences required for incorporation of an engineered ssRNA into the Reovirus genome.

Michael R Roner1, Kelly Bassett, Joanne Roehr.   

Abstract

Using a reovirus reverse genetics system, we have identified the 5' sequences required of an engineered s2 ssRNA for efficient incorporation into the dsRNA genome of Reovirus. Employing an engineered, functionally active reovirus S2/CAT gene retaining the first 198 5' terminal nucleotides and the last 284 3' terminal nucleotides of the wild-type S2 segment, we have determined the 5' sequence required by a ssRNA to be recognized, replicated to dsRNA, and stably incorporated into an infectious reovirus. The 5' sequence retains 96 nucleotides of the wild-type s2 ssRNA and a predicted sequence-structure element. Within these 96 nucleotides, we have identified three nucleotides A-U-U at positions 79-81 that are essential for the incorporation of in vitro-generated ssRNAs into new reovirus progeny viral particles. This study establishes a firm foundation for additional investigation into the assortment and encapsidation mechanism of all 10 ssRNAs into the dsRNA genome of reovirus.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15518814     DOI: 10.1016/j.virol.2004.08.026

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

1.  Rearranged genomic RNA segments offer a new approach to the reverse genetics of rotaviruses.

Authors:  Cécile Troupin; Axelle Dehée; Aurélie Schnuriger; Patrice Vende; Didier Poncet; Antoine Garbarg-Chenon
Journal:  J Virol       Date:  2010-04-28       Impact factor: 5.103

2.  Gene-specific inhibition of reovirus replication by RNA interference.

Authors:  Takeshi Kobayashi; James D Chappell; Pranav Danthi; Terence S Dermody
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  Generation of recombinant rotavirus with an antigenic mosaic of cross-reactive neutralization epitopes on VP4.

Authors:  Satoshi Komoto; Masanori Kugita; Jun Sasaki; Koki Taniguchi
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

4.  Reverse Genetics Approach for Developing Rotavirus Vaccine Candidates Carrying VP4 and VP7 Genes Cloned from Clinical Isolates of Human Rotavirus.

Authors:  Yuta Kanai; Misa Onishi; Takahiro Kawagishi; Pimfhun Pannacha; Jeffery A Nurdin; Ryotaro Nouda; Moeko Yamasaki; Tina Lusiany; Pattara Khamrin; Shoko Okitsu; Satoshi Hayakawa; Hirotaka Ebina; Hiroshi Ushijima; Takeshi Kobayashi
Journal:  J Virol       Date:  2020-12-22       Impact factor: 5.103

Review 5.  Reassortment in segmented RNA viruses: mechanisms and outcomes.

Authors:  Sarah M McDonald; Martha I Nelson; Paul E Turner; John T Patton
Journal:  Nat Rev Microbiol       Date:  2016-05-23       Impact factor: 60.633

6.  Rotavirus rearranged genomic RNA segments are preferentially packaged into viruses despite not conferring selective growth advantage to viruses.

Authors:  Cécile Troupin; Aurélie Schnuriger; Sarah Duponchel; Claire Deback; Nathalie Schnepf; Axelle Dehee; Antoine Garbarg-Chenon
Journal:  PLoS One       Date:  2011-05-17       Impact factor: 3.240

7.  The 3' sequences required for incorporation of an engineered ssRNA into the Reovirus genome.

Authors:  Michael R Roner; Joanne Roehr
Journal:  Virol J       Date:  2006-01-03       Impact factor: 4.099

8.  Reovirus Low-Density Particles Package Cellular RNA.

Authors:  Timothy W Thoner; Xiang Ye; John Karijolich; Kristen M Ogden
Journal:  Viruses       Date:  2021-06-08       Impact factor: 5.048

Review 9.  Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants.

Authors:  Adil Mohamed; Randal N Johnston; Maya Shmulevitz
Journal:  Viruses       Date:  2015-12-01       Impact factor: 5.048

Review 10.  Synthesis and Translation of Viral mRNA in Reovirus-Infected Cells: Progress and Remaining Questions.

Authors:  Guy Lemay
Journal:  Viruses       Date:  2018-11-27       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.